Recent advances in diagnosis and management of chronic cholestatic liver diseases: expert consensus
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250288Keywords:
Chronic cholestatic liver diseases, Obeticholic acid, Primary biliary cholangitis, Primary sclerosing cholangitis, Transient elastography, Ursodeoxycholic acidAbstract
Chronic cholestatic liver diseases (CCLD), primarily including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are characterized by impaired bile flow, leading to systemic complications such as pruritus, jaundice, fat soluble vitamin deficiencies and progressive liver damage. Recent advances in diagnostics, particularly the use of non-invasive tests like FIB-4, APRI and transient elastography, have significantly improved the early detection and assessment of liver fibrosis. Ursodeoxycholic acid (UDCA) remains the cornerstone treatment for PBC, effectively improving biochemical markers and delaying disease progression. In contrast, the treatment options for PSC remain limited. Emerging therapies targeting bile acid synthesis and gut microbiota modulation are under investigation, offering potential future solutions for PSC. In the Indian clinical setting, other causes of intrahepatic cholestasis, such as alcoholic liver disease (ALD) and drug-induced liver injury (DILI), are more prevalent. ALD with cholestasis is seen in 10-30% of patients, while DILI, often driven by tuberculosis medications and complementary and alternative medicines, accounts for a significant proportion of cases. Infectious causes like hepatitis A and fibrosing cholestatic hepatitis in hepatitis C patients post-liver transplantation also contribute to the disease burden. Experts recommend ongoing UDCA use in cholestatic conditions, regular non-invasive fibrosis assessments, and further research into new pharmacological agents for both PBC and PSC.
Metrics
References
Luo X, Lu LG. Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going? J Clin Transl Hepatol. 2024;12(6):581-8. DOI: https://doi.org/10.14218/JCTH.2023.00519
Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, et al. Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs. 2021;81(10):1181-92.
Ravindra BS, Lahoti R, Das K. Epidemiology and treatment practices of chronic cholestatic liver disease in India: a physician survey-based study. Int J Sci Rep. 2023;9(1):17-27. DOI: https://doi.org/10.18203/issn.2454-2156.IntJSciRep20223372
Devarbhavi H, Joseph T, Sunil Kumar N, Rathi C, Thomas V, Prasad Singh S, et al., The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients. J Clin Exp Hepatol. 2021;11(3):288-98. DOI: https://doi.org/10.1016/j.jceh.2020.11.002
Kim JY, Joung JY, Kang JY, Son CG, Cho JH. Acute viral hepatitis A with cholestatic hepatitis treated with traditional Korean medicine: a case report. The Journal of Korean Medicine. 2015;36(4):114-21. DOI: https://doi.org/10.13048/jkm.15038
Alebaji MB, Mehair AS, Shahrour OI, Elkhatib FA, Alkaabi EH, Alkuwaiti NS. Prolonged Cholestasis Following Acute Hepatitis A Infection: Case Report and a Review of Literature. Cureus. 2023;15(5):38511. DOI: https://doi.org/10.7759/cureus.38511
Muñoz-Martínez SG, Díaz-Hernández HA, Suárez-Flores D, Sánchez-Ávila JF, Gamboa-Domínguez A, García-Juárez I, et al. Atypical manifestations of hepatitis A virus infection. Rev Gastroenterol Mex (Engl Ed). 2018;83(2):134-43. DOI: https://doi.org/10.1016/j.rgmxen.2018.05.015
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1):58-68. DOI: https://doi.org/10.1016/j.jhep.2014.07.012
Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol. 2003;18(10):1118-28. DOI: https://doi.org/10.1046/j.1440-1746.2003.03165.x
Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol. 2017;32(7):1303-9. DOI: https://doi.org/10.1111/jgh.13738
Lu L, Chinese Medical Association. Guidelines for the management of cholestatic liver diseases (2021). Journal of Clinical and Translational Hepatology. 2022;10(4):757. DOI: https://doi.org/10.14218/JCTH.2022.00147
Gossard AA, Lindor KD. Medical management of chronic cholestatic liver diseases. Can J Gastroenterol. 2000;14:93-8. DOI: https://doi.org/10.1155/2000/871543
Levy C, Manns M, Hirschfield G. New Treatment Paradigms in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2023;21(8):2076-87. DOI: https://doi.org/10.1016/j.cgh.2023.02.005
Chang PE, Goh GB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther. 2016;7(1):91-106. DOI: https://doi.org/10.4292/wjgpt.v7.i1.91
Corpechot C. Noninvasive Evaluation of Fibrosis and Portal Hypertension in Primary Biliary Cholangitis. Clin Liver Dis. 2022;26(4):681-9. DOI: https://doi.org/10.1016/j.cld.2022.06.010
Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, et al., The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc. 2022;121(2):454-66. DOI: https://doi.org/10.1016/j.jfma.2021.07.013
León R, De Andrade Y, Guzman A, Fernández Bermúdez S, Romero J. Fib-4 en la valoración de fibrosis hepática determinada por elastografía transitoria 1D. Revista GEN.2024;78(1):3–6. DOI: https://doi.org/10.61155/2024.78.1.001
Hazzan R, Abu Ahmad N, Habib AS, Saleh I, Ziv N. Suboptimal reliability of FIB-4 and NAFLD-fibrosis scores for staging of liver fibrosis in general population. JGH Open. 2024;8(2):13034. DOI: https://doi.org/10.1002/jgh3.13034
Lazar A, Sporea I, Lungeanu D, Mare R, Lupusoru R, Popescu A, et al. The Prevalence of Liver Fibrosis Stages on More than 23,000 Liver Stiffness Measurements by Vibration-Controlled Transient Elastography: A Single Center Study. Diagnostics (Basel). 2023;13(17):2803. DOI: https://doi.org/10.3390/diagnostics13172803
Morgan MA, Khot R, Sundaram KM, Ludwig DR, Nair RT, Mittal PK, et al., Primary sclerosing cholangitis: review for radiologists. Abdom Radiol (NY). 2023;48(1):136-50. DOI: https://doi.org/10.1007/s00261-022-03655-6
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806.
Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al., Global PBC Study Group. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 2015;149(7):1804-12. DOI: https://doi.org/10.1053/j.gastro.2015.07.061
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. DOI: https://doi.org/10.1002/hep.30145
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-72.
Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al., RESPONSE Study Group. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024;390(9):783-94. DOI: https://doi.org/10.1056/NEJMoa2312100
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. LATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024;390(9):795-805. DOI: https://doi.org/10.1056/NEJMoa2306185
Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells. 2024;13(18):1580. DOI: https://doi.org/10.3390/cells13181580
Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, et al. cholestatic liver disease: current treatment strategies and new therapeutic agents. Drugs. 2021;81(10):1181-92. DOI: https://doi.org/10.1007/s40265-021-01545-7
Dubrovsky AMK, Bowlus CL. Statins, Fibrates and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases. Gastroenterol Hepatol (NY). 2020;16(1):31-8.
Hoofnagle JH, Björnsson ES. Drug-Induced Liver Injury - Types and Phenotypes. N Engl J Med. 2019;381(3):264-73. DOI: https://doi.org/10.1056/NEJMra1816149
Björnsson ES. Clinical management of patients with drug-induced liver injury (DILI). United European Gastroenterol J. 2021;9(7):781-6. DOI: https://doi.org/10.1002/ueg2.12113
Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019;20(3):122-6. DOI: https://doi.org/10.1111/1751-2980.12697
Robles-Díaz M, Nezic L, Vujic-Aleksic V, Björnsson ES. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. a systematic review. Front Pharmacol. 2021;12:744488. DOI: https://doi.org/10.3389/fphar.2021.744488
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81.
Plevris JN, Hayes PC, Bouchier IAD, Plevris, J. Ursodeoxycholic acid in the treatment of alcoholic liver-disease. European J Gastroenterol & Hepatol. 1991;3(9):653-6.
Nikolovska E, Miloshevski M, Chalovska-Ivanova V and Stardevola-Grivceva K. Long-term therapy with UDCA in the patients with alcoholic liver disease. Int J Anesth Pain Med. 2019;5:34-9.
Shah S, Gupta S. Evaluation of pharmacotherapies for alcoholic liver disease: a retrospective real-world evidence study. ERWEJ. 2022;2(2):87-99. DOI: https://doi.org/10.54136/ERWEJ-0202-10021
Fabris P, Tositti G, Mazzella G, Zanetti AR, Nicolin R, Pellizzer G, Benedetti P, de Lalla F. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther. 1999;13(9):1187-93. DOI: https://doi.org/10.1046/j.1365-2036.1999.00592.x
Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al., A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut. 2007;56(12):1747-53. DOI: https://doi.org/10.1136/gut.2007.120956
Arora A, Kumar A, Anand AC, Puri P, Dhiman RK, Acharya SK, et al., Indian National Association for the Study of the Liver-Federation of Obstetric and Gynaecological Societies of India Position Statement on Management of Liver Diseases in Pregnancy. J Clin Exp Hepatol. 2019;9(3):383-406. DOI: https://doi.org/10.1016/j.jceh.2019.02.007
Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016;95(40):4949. DOI: https://doi.org/10.1097/MD.0000000000004949
Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, et al., Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology. 2012;143(6):1492-501. DOI: https://doi.org/10.1053/j.gastro.2012.08.004
Grand'Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can. 2014;36(7):632-41. DOI: https://doi.org/10.1016/S1701-2163(15)30544-2
Ovadia C, Sajous J, Seed PT, Patel K, Williamson NJ, Attilakos G, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(7):547-58. DOI: https://doi.org/10.1016/S2468-1253(21)00074-1
Downloads
Published
How to Cite
Issue
Section
